Halozyme Therapeutics, Inc. (HALO)
67.30
-0.40
(-0.59%)
USD |
NASDAQ |
Dec 31, 16:00
67.17
-0.13
(-0.19%)
After-Hours: 20:00
Halozyme Therapeutics Cash from Investing (Quarterly): 201.61M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Johnson & Johnson | -542.00M |
| Merck & Co., Inc. | -283.00M |
| AIM ImmunoTech, Inc. | 0.296M |
| Bristol Myers Squibb Co. | -1.702B |
| Protalix Biotherapeutics, Inc. | -0.504M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 178.60M |
| Cash from Financing (Quarterly) | -22.40M |
| Free Cash Flow | 602.40M |
| Free Cash Flow Per Share (Quarterly) | 1.435 |
| Free Cash Flow to Equity (Quarterly) | 173.91M |
| Free Cash Flow to Firm (Quarterly) | 179.00M |
| Free Cash Flow Yield | 7.13% |